Idelalisib
About
Therapy type: Targeted therapy
Therapy strategy: PI3K/AKT/mTOR inhibition
Mappings
NCI Thesaurus: Idelalisib (coding:ncit:C78825)
RxNorm: idelalisib (coding:rxcui:1544460, coding:omop:45776944)
SNOMED: Idelalisib (coding:sctid:710278000, coding:omop:46271986)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| EMA (1) HSE (1) | TP53 Somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| EMA (1) HSE (1) | not 17p deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab |